# Ribavirin for Hemorrhagic Fever With Renal Syndrome

> **NCT00623168** · PHASE2 · WITHDRAWN · sponsor: **U.S. Army Medical Research and Development Command**

## Conditions studied

- Hemorrhagic Fever With Renal Syndrome

## Interventions

- **DRUG:** Ribavirin

## Key facts

- **NCT ID:** NCT00623168
- **Lead sponsor:** U.S. Army Medical Research and Development Command
- **Sponsor class:** FED
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2008-02
- **Primary completion:** 2019-12
- **Final completion:** 2019-12
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** This was an expanded access treatment protocol that did not enroll any subjects due to no infections requiring treatment.
- **Last updated:** 2025-06-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00623168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00623168, "Ribavirin for Hemorrhagic Fever With Renal Syndrome". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00623168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*